Results from a large prospective study indicate that gastroesophageal reflux disease (GERD), which also causes heartburn symptoms, is linked with higher risks of various cancers of the larynx (or voice box) and esophagus. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
GERD, a gastrointestinal disorder that affects approximately 20 percent of U.S. adults, occurs when stomach acid flows back into the esophagus, where it can cause tissue damage. Research indicates that this damage may put patients at risk of developing a type of cancer called esophageal adenocarcinoma.
To provide additional insights concerning this link and potential links to other types of cancer, a team led by Christian C. Abnet, PhD, of the National Cancer Institute, part of the National Institutes of Health (NIH), examined information on 490,605 adults enrolled in the NIH-AARP Diet and Health Study, a prospective study that mailed questionnaires in 1995-1996 to 3.5 million AARP members, aged between 50 and 71 years who were living in California, Florida, Louisiana, New Jersey, North Carolina, or Pennsylvania, or in the metropolitan areas of Atlanta, Georgia, and Detroit, Michigan.
Using Medicare claims data, the investigators estimated that 24 percent of participants had a history of GERD. Over the following 16 years after participants joined the study, 931 patients developed esophageal adenocarcinoma, 876 developed laryngeal squamous cell carcinoma, and 301 developed esophageal squamous cell carcinoma. People with GERD had about a two-times higher risk of developing each of these types of cancer, and the elevated risk was similar across groups categorized by sex, smoking status, and alcohol consumption. The investigators were able to replicate the results when they restricted analyses to the Medicare data subset of 107,258 adults.
The team estimated that approximately 17 percent of these cancers in the larynx and esophagus are associated with GERD.
"This study alone is not sufficient to result in specific actions by the public. Additional research is needed to replicate these findings and establish GERD as a risk factor for cancer and other diseases," said Dr. Abnet. "Future studies are needed to evaluate whether treatments aimed at GERD symptoms will alter the apparent risks."
###
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the Cancer News Room upon online publication. For more information or to obtain a PDF of any study, please contact:
Dawn Peters +1 781-388-8408 (US)
newsroom@wiley.com
Follow us on Twitter @WileyNews
Full Citation: "Gastroesophageal reflux disease: A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH-AARP Diet and Health Study cohort." Shao-Ming Wang, Neal D. Freedman, Hormuzd A. Katki, Charles Matthews, Barry I. Graubard, Lisa L. Kahle, and Christian C. Abnet. CANCER; Published Online: February 22, 2021 (DOI: 10.1002/cncr.33427).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.33427
Author Contact: The National Cancer Institute's Press Office, at ncipressofficers@mail.nih.gov.
About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online.
Follow us on Twitter @JournalCancer
About Wiley
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at http://www.wiley.com.
Journal
Cancer